GLOBAL PLASMA PROTEIN THERAPEUTIC MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Plasma protein therapeutic refers to therapeutic products that are derived from human blood plasma and are used for treating various medical conditions such as chronic disease and others. Blood plasma contains over 700 different proteins and serves various important functions in the body. Some of the major plasma protein therapeutics include immunoglobulins, coagulation factors, albumin, and other specialty proteins. These plasma derived products help in boosting the immune system, blood clotting, and other metabolic processes. With the growing geriatric population suffering from chronic diseases, there has been a rise in the demand for plasma therapeutics globally. Also, advanced purification technology has enabled significant yield of critical proteins from plasma in a cost-effective manner.

 Market Dynamics:

The global plasma protein therapeutic market is driven by the rising prevalence of immune deficiency diseases and genetic disorders requiring plasma replacement therapies. The growing geriatric population prone to chronic illnesses like bleeding disorders is also supporting the demand. Continuous R&D efforts to develop new plasma-derived products and wider coverage under medical insurance schemes are providing opportunities in this space. However, stringent regulations pertaining to plasma collection and high capital requirements for plasma fractionation plants act as challenges. Also, the emergence of alternative recombinant therapies threatens the market growth. Safety concerns around plasma sourcing if not properly screened also hinder the market growth.

For instance, on June 26, 2023, according to a report published by the National Center for Biotechnology Information, in 2021, in South Korea, the occurrence rate of primary immunodeficiencies (PID) stood at around 11.25 cases per million children. The most commonly identified immunodeficiencies were those related to antibodies, constituting 53.3%, with phagocytic disorders trailing at 28.9%.

Key features of the study:

• This report provides an in-depth analysis of the global plasma protein therapeutic market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period 2026-2033, considering 2025 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends,  regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global plasma protein therapeutic market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Octapharma USA Inc., Biotest AG, Kedrion S.p.A, CSL Limited, Grifols, S.A, Takeda Pharmaceutical Company Limited., Octapharma AG, Bio Products Laboratory (BPL), Shire Plc, and Albumedix Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global plasma protein therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global plasma protein therapeutic market

Global Plasma Protein Therapeutic Market Detailed Segmentation:

• By Product Type (Revenue, USD Bn, 2021 - 2033)
  • Albumin
  • Immunoglobulin
  • Plasma-derived Factor VIII
  • Others
• By Application (Revenue, USD Bn, 2021 - 2033)
  • Haemophilia
  • Primary Immunodeficiency Disorder (PIDD)
  • Idiopathic Thrombocytopenic Purpura (ITP)
  • Others
• By End User (Revenue, USD Bn, 2021 - 2033)
  • Hospitals
  • Clinics
  • Research Laboratories
  • Others

• Regional Insights (Revenue, USD Bn, 2021 - 2033)

  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Top Companies in the Global Plasma Protein Therapeutic Market:
  • Octapharma USA Inc.
  • Biotest AG
  • Kedrion S.p.A
  • CSL Limited
  • Grifols, S.A
  • Takeda Pharmaceutical Company Limited.
  • Octapharma AG
  • Bio Products Laboratory (BPL)
  • Shire Plc
  • Albumedix Ltd.